These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 23671280)

  • 21. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.
    Honda R; Tanaka H; Yasuda H
    FEBS Lett; 1997 Dec; 420(1):25-7. PubMed ID: 9450543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inactivation of the MDM2 RING domain enhances p53 transcriptional activity in mice.
    Tian H; Tackmann NR; Jin A; Zheng J; Zhang Y
    J Biol Chem; 2017 Dec; 292(52):21614-21622. PubMed ID: 29123033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual-site regulation of MDM2 E3-ubiquitin ligase activity.
    Wallace M; Worrall E; Pettersson S; Hupp TR; Ball KL
    Mol Cell; 2006 Jul; 23(2):251-63. PubMed ID: 16857591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mdm2 Splice isoforms regulate the p53/Mdm2/Mdm4 regulatory circuit via RING domain-mediated ubiquitination of p53 and Mdm4.
    Fan C; Wang X
    Cell Cycle; 2017 Apr; 16(7):660-664. PubMed ID: 28166445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53.
    Wang L; He G; Zhang P; Wang X; Jiang M; Yu L
    Mol Biol Rep; 2011 Jan; 38(1):229-36. PubMed ID: 20333547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53.
    Buschmann T; Fuchs SY; Lee CG; Pan ZQ; Ronai Z
    Cell; 2000 Jun; 101(7):753-62. PubMed ID: 10892746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. UBE4B, a ubiquitin chain assembly factor, is required for MDM2-mediated p53 polyubiquitination and degradation.
    Wu H; Leng RP
    Cell Cycle; 2011 Jun; 10(12):1912-5. PubMed ID: 21558803
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RNF12 promotes p53-dependent cell growth suppression and apoptosis by targeting MDM2 for destruction.
    Gao K; Wang C; Jin X; Xiao J; Zhang E; Yang X; Wang D; Huang H; Yu L; Zhang P
    Cancer Lett; 2016 May; 375(1):133-141. PubMed ID: 26926424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A site-directed mutagenesis study of the MdmX RING domain.
    Egorova O; Mis M; Sheng Y
    Biochem Biophys Res Commun; 2014 May; 447(4):696-701. PubMed ID: 24755078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of p53 degradation by Mdm2 acetylation.
    Wang X; Taplick J; Geva N; Oren M
    FEBS Lett; 2004 Mar; 561(1-3):195-201. PubMed ID: 15013777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural analysis of MDM2 RING separates degradation from regulation of p53 transcription activity.
    Nomura K; Klejnot M; Kowalczyk D; Hock AK; Sibbet GJ; Vousden KH; Huang DT
    Nat Struct Mol Biol; 2017 Jul; 24(7):578-587. PubMed ID: 28553961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MDM2 acts downstream of p53 as an E3 ligase to promote FOXO ubiquitination and degradation.
    Fu W; Ma Q; Chen L; Li P; Zhang M; Ramamoorthy S; Nawaz Z; Shimojima T; Wang H; Yang Y; Shen Z; Zhang Y; Zhang X; Nicosia SV; Zhang Y; Pledger JW; Chen J; Bai W
    J Biol Chem; 2009 May; 284(21):13987-4000. PubMed ID: 19321440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mdm2 and MdmX partner to regulate p53.
    Wang X; Jiang X
    FEBS Lett; 2012 May; 586(10):1390-6. PubMed ID: 22673503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of a Catalytic Active but Non-Aggregating MDM2 RING Domain Variant.
    Magnussen HM; Huang DT
    J Mol Biol; 2021 Mar; 433(5):166807. PubMed ID: 33450248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53.
    Honda R; Yasuda H
    EMBO J; 1999 Jan; 18(1):22-7. PubMed ID: 9878046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ATM activates p53 by regulating MDM2 oligomerization and E3 processivity.
    Cheng Q; Chen L; Li Z; Lane WS; Chen J
    EMBO J; 2009 Dec; 28(24):3857-67. PubMed ID: 19816404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53 stability in response to DNA damage.
    Fu X; Yucer N; Liu S; Li M; Yi P; Mu JJ; Yang T; Chu J; Jung SY; O'Malley BW; Gu W; Qin J; Wang Y
    Proc Natl Acad Sci U S A; 2010 Mar; 107(10):4579-84. PubMed ID: 20173098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human mdm2 mediates multiple mono-ubiquitination of p53 by a mechanism requiring enzyme isomerization.
    Lai Z; Ferry KV; Diamond MA; Wee KE; Kim YB; Ma J; Yang T; Benfield PA; Copeland RA; Auger KR
    J Biol Chem; 2001 Aug; 276(33):31357-67. PubMed ID: 11397792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53 Ubiquitination and proteasomal degradation.
    Love IM; Shi D; Grossman SR
    Methods Mol Biol; 2013; 962():63-73. PubMed ID: 23150437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MAGE-A Cancer/Testis Antigens Inhibit MDM2 Ubiquitylation Function and Promote Increased Levels of MDM4.
    Marcar L; Ihrig B; Hourihan J; Bray SE; Quinlan PR; Jordan LB; Thompson AM; Hupp TR; Meek DW
    PLoS One; 2015; 10(5):e0127713. PubMed ID: 26001071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.